Edwards Lifesciences Corporation
What does the company do — and does the stock price make sense?

How does the company make money?

Edwards develops and sells artificial heart valves and devices for treating diseased heart valves. Many products can be inserted through a thin tube; others are used during surgery.

What supports the business?

Edwards is growing not just revenue: operating profit rose by around 25% in the second quarter. New heart valve treatments complement the established business.

What could improve?

If more patients receive the new mitral and tricuspid valve treatments, Edwards could further increase its earnings. This is a genuine growth opportunity, but not a guaranteed share-price increase.

How is the stock price assessed?

86.39 USD seem demanding to me: the price is about 28 to 29 times the 2026 expected earnings after excluding certain special items. Actual cash surpluses so far provide substantially less support.

What is the main risk?

The price assumes that new treatments will grow successfully and generate sufficient cash for years. Delayed approvals, competition, or additional tax burdens could disappoint these expectations.

What is the overall assessment?

Operationally compelling heart valve specialist with strong financing, but valued aggressively at 86.39 USD. The documented improvement warrants attention; cash generation to date and continuing pressures on results are not yet convincing enough to support a positive overall balance of price and risks.

Sources used in the analysis

1. Original source 1 · api-v4.fcsapi.com
2. Original source 2 · data.sec.gov
3. Original source 3 · www.sec.gov · Feb 25, 2026
4. Original source 4 · www.sec.gov · Aug 04, 2026
5. Original source 5 · ir.edwards.com · Jul 23, 2026
6. Original source 6 · www.sec.gov
7. Original source 7 · www.edwards.com · Jan 09, 2026
8. Original source 8 · www.edwards.com · Oct 07, 2026